CSIMarket Company Name, Ticker, Customers, else..
 
Heartsciences Inc   (NASDAQ: HSCS)
Other Ticker:  
 
 
Price: $3.8000 $0.00 -0.058%
Day's High: $3.8 Week Perf: 12.43 %
Day's Low: $ 3.79 30 Day Perf: 2.98 %
Volume (M): 2 52 Wk High: $ 18.50
Volume (M$): $ 8 52 Wk Avg: $5.80
Open: $3.79 52 Wk Low: $2.36



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0

Heartsciences Inc
Heart Test Laboratories Inc is a medical diagnostic company that focuses on heart health. They offer a range of tests and services to assess and monitor heart conditions in patients. Their innovative technology and skilled team of professionals enable accurate and efficient heart screenings, aiming to provide early detection and prevention of cardiovascular diseases. They are dedicated to improving patient outcomes and reducing the risks associated with heart-related conditions.


   Company Address: 550 Reserve Street Southlake 76092 TX
   Company Phone Number: 237-7781   Stock Exchange / Ticker: NASDAQ HSCS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IRTC        1.03% 
LFST   -1.62%    
MASI        2.34% 
NIMU   -58.18%    
PIII        2.91% 
ABT        0.79% 
• View Complete Report
   



Financing Agreement

HeartSciences Secures $1.9 Million Financing to Propel AI-Driven ECG Innovations Ahead of FDA Submission
n,

Published Thu, Sep 12 2024 1:00 PM UTC

nnRevolutionizing Cardiovascular Care: HeartSciences Secures Non-Dilutive Financing Ahead of FDA Submissionnn
In a groundbreaking move that underscores the growing intersection of artificial intelligence (AI) and healthcare, HeartTest Laboratories, Inc., operating as HeartSciences (NASDAQ: HSCS; HSCSW), has recently closed a significant $1.9 million non-dilutive financin...
Product Service News

Advancements in Cardiovascular Care HeartSciences MyoVista wavECG Promises Enhanced Efficiency

Published Fri, Jul 26 2024 1:00 PM UTC

In a significant development for cardiovascular healthcare, Heart Test Laboratories, Inc., operating as HeartSciences, has announced findings that suggest its MyoVista wavECG technology has the potential to greatly improve efficiency within the cardiovascular pathway. The analysis, published by the Innovation Value Institute (IVI), emphasizes the role of artificial intellige...
Heart Test Laboratories Inc

Advanced Heart Test Laboratories Inc. Witnesses Promising Revenue Similar to Previous Year's Quarter, as Efforts Focus on Q1 2024



Heart Test Laboratories Inc, a medical device manufacturing company, recently released its financial results for the first quarter of the 2024 earnings season. The figures demonstrate a significant decrease in loss per share compared to the previous year, as well as an improvement in earnings per share. Although the revenue remained unchanged, the company reported a lower net shortfall compared to the same reporting season the previous year. This article aims to provide an overview of Heart Test Laboratories Inc's Q1 2024 financial results and analyze them within the context of recent stock performance.
Financial Results:
Heart Test Laboratories Inc reported a loss per share of $-0.13 in the first quarter of 2024, a considerable improvement from the loss per share of $-0.28 in the same reporting season the previous year. Additionally, the company's earnings per share increased from $-0.16 in the previous reporting season. Despite these positive developments, the revenue for Q1 2024 remained unchanged at $0.00 million, both compared to the same reporting season a year before and sequentially.
Heart Test Laboratories Inc

Breaking News: Biotech Firm HSCS Reveals Surprising Q4-2023 Financial Results; Shareholders in Shock! and Unexpected Financial Developments at Heart Test Laboratories Inc. in Q1 2023, Operating Shortfall Reaches $1.6 Million.



In the surprising turn of events, Heart Test Laboratories Inc, a leading Biotechnology & Pharmaceuticals company, has recently reported financial results that deviated from the stockholders' expectations. The company's operating shortfall amounted to $-1.598659 million during the earnings season of February to April 2023. Moreover, Heart Test Laboratories Inc recorded a net loss of $-1.632 million, as opposed to break-even in the corresponding reporting period the previous year. These unforeseen results have left investors wondering about the potential implications for the company's future.
1. Narrowing Margins:
The operating shortfall of $-1.598659 million during the latest earnings season indicates that Heart Test Laboratories Inc struggled to generate sufficient revenue to cover its operating expenses. This suggests that the company's gross margins may have contracted during this period. Such a decline in margins may raise concerns among stockholders regarding the overall financial health and profitability of the company.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com